C肽质量浓度与2型糖尿病神经病变的相关性研究

doi:10.3969/j.issn.1006-7795.2018.01.023

摘要/Abstract

摘要： 目的探讨2型糖尿病（type 2 diabetes mellitus，T2DM）患者血清C肽（C-peptide，C-P）质量浓度与神经病变的关系。方法回顾性分析426名T2DM患者的临床资料，根据其血清C-P质量浓度分为3组，由低到高分别为C-P1（≤ 1.7 μg/L）152例，C-P2（1.8~2.7 μg/L）137例，C-P3（≥ 2.8 μg/L）137例。结果低C-P组体质量指数（body mass index，BMI）、三酰甘油（triglyceride，TG）、尿酸（uric acid，UA）、空腹胰岛素（fasting insulin，FINS）质量浓度低于高C-P组（P<0.05），高密度脂蛋白胆固醇（high density lipoprotein cholesterol，HDL-C）、病程、糖尿病周围神经病变（diabetic peripheral neuropathy，DPN）和糖尿病心脏自主神经病变（diabetic cardiac autonomic neuropathy，DCAN）发病率高于高C-P组，且C-P质量浓度越低，合并症发病率越高（P<0.05）。DPN及DCAN患者的血清C-P质量浓度均低于非糖尿病周围神经病变（nondiabetic peripheral neuropathy，NDPN）及非糖尿病心脏自主神经病变（nondiabetic cardiac autonomic neuropathy，NDCAN）患者（P<0.05）。C-P质量浓度与BMI、TG、UA、FINS浓度正相关（P<0.05），与HDL、低密度脂蛋白胆固醇（low density lipoprotein cholesterol，LDL-C）、空腹血糖（fasting plasma glucose，FPG）、病程、DPN发病率、DCAN发病率呈负相关（P<0.05）。Logistic回归分析显示，在校正了相关因素后，病程和较低的C-P质量浓度是糖尿病神经病变发生的独立危险因素。结论血清C-P质量浓度是T2DM周围神经病变和心脏自主神经病变的独立相关因素。

关键词: 2型糖尿病, 周围神经病变, 心脏自主神经病变, C肽

Abstract: Objective To investigate the relationship between the level of serum C-peptide(C-P) and neuropathy in patients with type 2 diabetes mellitus(T2DM).Methods The clinical data of 426 patients with T2DM was retrospectively analyzed. These patients were divided into three groups according to their serum C-P levels. From low to high were C-P(≤ 1.7 μg/L) in 152 cases,C-P2(1.8-2.7 μg/L)in 137 cases,C-P3(≥ 2.8 μg/L) in 137 cases.Results The levels of body mass index(BMI), triglyceride(TG), uric acid(UA) and fasting insulin(FINS) in the group of low C-P were lower than those in high C-P group(P<0.05). The levels of high density lipoprotein cholesterol(HDL-C), course and the incidence of diabetic peripheral neuropathy(DPN) and diabetic cardiac autonomic neuropathy(DCAN) were higher than those in high C-P group. The lower level of C-P, the higher incidence of complications(P<0.05). Serum C-P levels in patients with DPN and DCAN were lower than those of nondiabetic peripheral neuropathy(NDPN) and nondiabetic cardiac autonomic neuropathy(NDCAN) (P<0.05). The level of C-P was positively related to the levels of BMI, TG, UA and FINS (P<0.05), and negatively related to HDL-C, low density lipoprotein cholesterol(LDL-C), fasting plasma glucose(FPG), course, incidence of DPN and DCAN(P<0.05). Logistic regression analysis showed that the course and the low level of C-P were independent risk factors of diabetic neuropathy complications after correction of related factors.Conclusion Serum C-P level is independently associated with peripheral neuropathy and cardiac autonomic neuropathy in T2DM.

Key words: type 2 diabetes mellitus, peripheral neuropathy, cardiac autonomic neuropathy, C-peptide

中图分类号:

R587.1

卢丙艳, 董静莲. C肽质量浓度与2型糖尿病神经病变的相关性研究[J]. 首都医科大学学报, 2018, 39(1): 133-137.

Lu Bingyan, Dong Jinglian. Relationship of C-peptide levels and neuropathy in type 2 diabetes mellitus[J]. Journal of Capital Medical University, 2018, 39(1): 133-137.

参考文献

[1] Luppi P, Kallas Å, Wahren J. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?[J]. Diabetes Metab Res Rev, 2013, 29(5):357-362.
[2] Paterson A D, Rutled B N, Cleary P A,et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes:the diabetes control and complications trial/epidemiology of diabetes interventions and complicationsstudy[J]. Diabetes Care, 2007, 30(8):2107-2112.
[3] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications:report of a World Health Organisation Collaborations[J]. Diabet Med, 1999, 15(7):539-553.
[4] Gabir M M, Hanson R L, Dabelea D, et al. The 1997 American diabetes association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes[J]. Diabetes Care, 2000, 23(8):1108-1112.
[5] 中国医师协会内分泌代谢科医师分会. 糖尿病周围神经病变诊疗规范(征求意见稿)[J]. 中国糖尿病杂志, 2009, 17(8):638-640.
[6] Tesfaye S,Boulton A J,Dyck P J, et al. Diabetic neuropathies:update on definitions,diagnostic criteria, estimation of severity,and treatments[J].Diabetes Care,2010, 33(10):2285-2293.
[7] Ekberg K, Brismar T, Johansson B L, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy[J]. Diabetes Care, 2007, 30(1):71-76.
[8] Ekberg K, Johansson B L. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes[J]. Exp Diabetes Res, 2008, 2008(1):457912.
[9] 张东铭, 王崇贤, 张苏河. 2型糖尿病周围神经病变与C肽水平的相关性研究[J]. 中国实用神经疾病杂志, 2011, 14(3):12-14.
[10] 陈晓蕾, 宋滇平, 罗平. 2型糖尿病患者血清C肽水平与尿白蛋白肌酐比及神经传导速度的关系[J]. 中国糖尿病杂志, 2008, 16(6):334-337.
[11] Schmeichel A M, Schmelzer J D, Low P A. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy[J]. Diabetes, 2003, 52(1):165-171.
[12] Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide[J]. Diabetologia, 2007, 50(3):503-509.
[13] Jannot M F, Raccah D, De La Tour D D, et al. Genetic and environmental regulation of Na/K adenosine triphosphatase activity in diabetic patients[J]. Metabolism, 2002, 51(3):284-291.
[14] Matthews D R, Cull C A, Stratton I M, et al. UKPDS 26:Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group[J]. Diabet Med, 1998, 15(4):297-303.
[15] 马璐璐, 苏绍娟, 谭明珠,等. 不同病程糖尿病患者血清C肽水平变化及意义[J]. 山东医药, 2015,55(27):82-84.